In the high-stakes world of oncology, time is the most precious currency. For patients, it is the difference between life and death; for clinicians, it is an increasingly scarce resource. Since its inception more than a decade ago, the American Society of Clinical Oncology’s (ASCO) CancerLinQ platform was designed to act as a vast repository of electronic health record (EHR) data, attempting to turn routine patient encounters into a massive "learning system." However, the platform has recently undergone a seismic shift in purpose and capability.
Following its acquisition by ConcertAI—a leader in AI-powered oncology and real-world data—in December 2023, CancerLinQ has evolved from a tool primarily used for automated quality reporting into a sophisticated, agentic AI platform. This transformation represents a fundamental change in how oncologists interact with patient data, moving from reactive record-keeping to proactive, point-of-care decision support.
The Chronology of a Data Revolution
To understand the current state of CancerLinQ, one must first look at its origins. Launched by ASCO to help practices harmonize disparate EHR data, the platform’s early years were dominated by the administrative necessity of quality measurement.
"Before we bought it, CancerLinQ largely just delivered software that automated the measurement of ASCO certification quality measures, in order to get your ASCO certification," explains Eron Kelly, CEO of ConcertAI.
The December 2023 acquisition marked a turning point. ConcertAI recognized that the platform was sitting on a goldmine of longitudinal, real-world evidence that remained largely dormant. By integrating ConcertAI’s proprietary AI engine, the new owners began to build a stack that could ingest, structure, and synthesize complex clinical information. Throughout 2024 and 2025, the company aggressively expanded the platform’s features, shifting the focus from simple reporting to clinical decision support (CDS) and automated trial matching.
Closing the Care-Research Gap: Data as a Catalyst
The primary objective behind this evolution is the closure of the persistent gap between routine clinical care and the latest advances in research. In oncology, the speed of therapeutic innovation—particularly with immunotherapy and targeted agents—often outpaces the ability of community practices to identify which patients might benefit from these emerging treatments.
Dr. Shaalan Beg, ConcertAI’s Chief Medical Officer of Oncology, highlights the critical nature of this mission. He points to recent ASCO data showing that, for metastatic pancreatic cancer, a new agent can nearly double median survival from six months to 12 months.
"If you’re a pancreatic cancer patient right now and you want the best standard of care," Dr. Beg notes, "the only way you’re going to get it is through clinical trials."
ConcertAI aims to bridge this divide by making the platform agnostic to EHR vendors and genomic laboratory systems. By creating a unified, structured data model from fragmented inputs—physician notes, pathology reports, and genomic sequencing—the platform allows for real-time identification of patients who meet the rigorous criteria for cutting-edge clinical trials.
The "Lane Assist" Model for Oncology
Perhaps the most compelling analogy for the platform’s current functionality comes from Dr. Beg, who likens the AI’s role to "lane assist" in a modern vehicle.
"For most of the clinical care doctors are asking for right now, it’s more like lane assist—keeping the car in its lane and giving nudges along the way," he explains.
These "nudges" are not meant to replace the physician’s judgment but to prevent critical omissions. The system might alert a doctor that a colon cancer patient is missing essential molecular profiling data or suggest a specific clinical trial that matches the patient’s profile. This workflow-integrated approach is essential, as the sheer complexity of modern oncology has long outgrown the capacity of any single clinician.
The era of the "all-knowing" solo physician is effectively over. Today’s care involves a multi-disciplinary team of nurse practitioners, geneticists, dietitians, and physical therapists. ConcertAI acts as the glue that keeps this fragmented team aligned, reducing the administrative burden that leads to physician burnout.
Supporting Data: The Surge in AI Adoption
The transition toward AI-assisted oncology is backed by a rapid shift in physician sentiment. Data from the American Medical Association (AMA) illustrates this trend clearly. In 2023, approximately 38% of physicians were incorporating AI into their clinical practice. By 2026, that figure climbed to 72%. Similarly, awareness of AI’s potential in the medical field jumped from 66% to 81% over the same period.
The most popular applications for this technology, according to the AMA, are documentation and summarization. Physicians are increasingly relying on AI to parse lengthy charts and synthesize research, a use case that has surged by 26 percentage points since 2024. ConcertAI’s platform capitalizes on this by allowing clinicians to query the software stack for insights that would otherwise take hours of manual chart review to uncover.
The Architecture of Trust: How the AI Works
The technical underpinnings of this transformation rely on a "chain of AI models and agents." According to Eron Kelly, the system parses unstructured data—such as narrative physician notes and complex pathology reports—and transforms them into a structured, queryable data model.
"We use a chain of AI models and agents to parse all that information, understand really challenging concepts like progression, or timelines within a diagnosis journey, and summarize that into a structured data model," Kelly says.
To ensure clinical accuracy and maintain trust, ConcertAI employs a multi-layered verification process. One layer checks for "abstraction accuracy," ensuring the model correctly interprets the chart. A secondary layer checks for "coherence," flagging clinical sequences that don’t make medical sense, such as a treatment regimen that logically follows a different line of therapy.
This level of scrutiny is vital for the "re-discovery" of patient populations. For example, by re-analyzing historical pathology data, the platform can identify patients who were previously classified as "HER2-negative" but would now be eligible for newer, highly effective antibody-drug conjugates (ADCs) under updated clinical criteria.
Implications for the Future: "Ground Shots" vs. "Moonshots"
While the medical community has long been captivated by the "Moonshot" approach to cancer—the search for a singular, miraculous cure—Dr. Beg advocates for what he calls "ground shots."
"I think we should focus on ground shots first, disseminating the treatments we already know work to the people who need them right now," he says.
The implication for the future of healthcare is profound. By leveraging agentic AI to handle the heavy lifting of data synthesis, screening, and trial matching, ConcertAI is fundamentally changing the economics of oncology. These tools allow a single, overburdened clinical trials office to process a higher volume of patients, reaching those at satellite sites that were previously disconnected from academic research centers.
As CancerLinQ continues to scale, it serves as a blueprint for the future of medical technology. It demonstrates that the path to improved outcomes may not always lie in discovering new molecules, but in the intelligent, data-driven application of the therapies we already possess. By providing clinicians with the right information at the exact moment of decision-making, the platform is effectively turning the promise of precision medicine into a repeatable, scalable clinical reality.
In the final analysis, the acquisition of CancerLinQ by ConcertAI has done more than just update a software platform; it has signaled the maturation of AI from an experimental curiosity into an essential, life-saving component of the oncology workflow. As the technology continues to evolve, the "lane assist" provided by these intelligent systems may soon become the standard of care for patients worldwide.
About the Author
